Across TCGA pan-cancer cohorts, FANCL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FANCL data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher FANCL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FANCL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
COAD, PRAD, and SKCM are the cancer types where FANCL Mutation most reproducibly stratifies survival.